logo
A Psychologist Reveals The Profession With The Highest Infidelity Rates

A Psychologist Reveals The Profession With The Highest Infidelity Rates

Forbes12 hours ago

Healthcare professions might create stressful conditions that can fuel infidelity. Does this mean no ... More medical worker can be trusted in love? Here's the objective answer.
No one ever wants to be cheated on. In fact, the fear of infidelity often drives us to panic and seek answers — who does it, why they do it and how to prevent it — so that we never have to face that kind of pain in our relationships.
In our search for answers and self-protection, we'll look for patterns that can tell us which kind of person is most likely to cheat on us. But when these patterns turn into unproven generalizations, it can be dangerous.
In 2018, Ashley Madison, a controversial dating service for those who are already married or in relationships, asked over 1000 users what they did for a living. Among women using the site for extra-marital affairs, the most commonly reported profession was working in medicine, with 23% of users working as doctors or nurses. 5% of male users also worked in medicine.
'A combination of long hours of potential stress mixed with a natural reaction to stress just might be the reason these women in the medical profession seek out an affair,' suggests Isabella Mise, Director of Communications at Ashley Madison.
More recently in 2025, another extra-marital dating service from the UK, called Illicit Encounters, appears to have reaffirmed this finding, reporting that nurses make up the largest proportion of female users on their website.
Many are questioning the truth and weight behind these claims, considering that these reports are based on users who chose to use these sites for affairs, and do not represent the entire industry of healthcare workers. Sure, some nurses might cheat. But are all nurses prone to cheating?
To avoid giving in to misconceptions and stereotypes, it's essential to look at the evidence objectively.
Could Nurses Be More Prone To Cheating?
Healthcare workers often have to manage long and unpredictable work hours, high-stress situations and the emotional weight of their work, which can cause grief, exhaustion, anxiety and severe mental and physical burnout.
A 2017 study published in the Journal of Clinical Nursing assessed the levels of burnout in nursing home caregivers in France, and found that 40% of participants struggled with caregiver burnout.
Often, the tendency to cheat has been attributed to the stressful nature of such work.
In a 2021 study of over 360 doctors and nurses, published in the International Journal of Environmental Research and Public Health, researchers found that 21% of participants were either currently in or had been in an unfaithful relationship in the past, and over 80% of such individuals were doctors.
Interestingly, in contrast to the trope of adulterous female nurses, researchers found that men in the study were almost five times more likely to cheat than women, with men also being more likely to engage in sex in the doctor's room while on duty.
Work hours also seemed to play a role in this pattern. People who worked on the nighttime emergency schedule were almost 18 times more likely to be unfaithful to their partners than those who worked part-time.
Participants blamed the demands of their job, including having to spend time away from home for many hours and needing to release their stress. They also admitted that because of their work, it was easier to justify their absence at home, and likely easier to cover up their infidelity.
However, it's essential to remember that correlation is not causation. While their occupation may have created conditions that tested them, the choice to be unfaithful was still deeply personal.
Could professions like healthcare create conditions that facilitate infidelity? Certainly. Does being a part of that profession inevitably and directly cause infidelity? Absolutely not.
Who Really Cheats?
Here are some of the most salient reasons why people cheat, that have much more to do with themselves, than what profession they're in:
Regardless of the context, infidelity ultimately appears to be the result of deep internal conflict, rather than external temptation. Rather than focusing on what a person who cheats does for work, it's time to start paying attention to the fact that they haven't necessarily done the inner work to bring open communication, vulnerability and honesty to their relationships.
Wondering if you might ever be driven to cheat on your partner? Take the science-backed Propensity Towards Infidelity Scale to learn more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Data at EULAR Signal Advances in RA, Myopathy, Gout
New Data at EULAR Signal Advances in RA, Myopathy, Gout

Medscape

time42 minutes ago

  • Medscape

New Data at EULAR Signal Advances in RA, Myopathy, Gout

Barcelona has become the world capital of rheumatology by hosting the 2025 Annual Meeting of the European Alliance of Associations for Rheumatology (EULAR) in Spain. 'This is the world's largest rheumatology event,' said Daniel Aletaha, MD, president of EULAR and head of the Department of Rheumatology at the University Clinic for Internal Medicine III, MedUni Vienna, Vienna, Austria, during the conference opening session. He highlighted the scale of participation: 5125 abstracts submitted from 95 countries, 117 sessions, and 350 speakers from 45 nations. Inflammatory and Autoimmune Disease Among the plenary highlights was research led by Jason D. Turner, PhD, a postdoctoral research fellow at the University of Birmingham, Birmingham, England. His comparative analysis of synovial tissue using single-cell and spatial transcriptomics identified overlapping disease pathways in spontaneous inflammatory arthritis and arthritis induced by immune checkpoint inhibitors. 'We found that the synovium in checkpoint inhibitor-associated arthritis is enriched with fibroblasts and T cells, is highly vascularised, and contains large numbers of CXCL9/10/11+ macrophages and CD8+ T cells. These findings support the current use of tumour necrosis factor inhibitors for this condition, although further investigation is needed to understand their applicability to spontaneous arthritis,' Turner explained. Hector Chinoy, PhD, FRCP, professor of rheumatology at the University of Manchester and lead at the Salford Royal Adult Neuromuscular Service, Manchester, England, presented the results of the ALKIVIA phase 2 study. This trial evaluated the efficacy of subcutaneous efgartigimod (PH20) administration in adults with active idiopathic inflammatory myopathy. The drug led to significant improvements in the Total Improvement Score compared with placebo and showed good tolerability and safety. 'These findings demonstrate the mechanistic importance of neonatal Fc receptor inhibition and suggest a potential pathogenic role for autoantibodies. These findings support the continued evaluation of the drug in the ongoing phase 3 trial' Chinoy said. Scleroderma, Preclinical Rheumatoid Arthritis (RA), Gout, and Lupus Adela‑Cristina Sarbu, MD, a researcher specialising in systemic sclerosis and interstitial lung disease at the University Hospital Bern, Bern, European Scleroderma Trials and Research group (EUSTAR), and the University of Zurich, Zurich, Switzerland, presented the findings from the EUSTAR cohort. In conclusion, exposure to prostanoids appeared to be associated with a slower progression of interstitial lung disease in patients with mild vascular disease. In contrast, exposure to endothelin receptor antagonists appeared to be beneficial in preventing symptom worsening in patients with more severe vascular diseases. 'No independent mortality benefit was seen with vasoactive or vasodilator drugs. Their effectiveness seems to depend on the severity of vascular disease' Sarbu noted, calling for further long-term studies. The ALTO study, an extension of the APIPPRA trial, led by Andrew Cope, PhD, of King's College London, London, England, found that a 1-year course of abatacept in individuals at high risk of developing RA could delay disease onset by up to 4 years. 'Individuals with baseline autoantibody profiles are more likely to develop the disease and respond well to T-cell co-stimulation blockade. Abatacept reduces the symptom burden during treatment but does not provide sustained benefits after treatment discontinuation. No new safety concerns were reported,' according to Cope. Edoardo Cipolletta, MD, rheumatologist at the Marche University Hospital, Ancona, Italy, and research associate at the University of Nottingham, Nottingham, England, presented an analysis of data on primary care, hospitalization, and mortality outcomes related to gout, based on cohorts from the UK and Sweden. The study found that achieving serum urate levels below 360 µmol/L within a year of initiating urate-lowering treatment was associated with a significantly lower risk for major adverse cardiovascular events. The 5-year relative risk reduction ranged from 6% to 11%, with an absolute survival benefit of 1.3%-1.4%. 'The association was consistent regardless of prior cardiovascular disease and across all sensitivity analyses,' Cipolletta reported. Richard A. Furie, MD, chief of Rheumatology at Northwell Health in New York, presented results from the REGENCY study, which evaluated obinutuzumab in patients with lupus nephritis. Award Recognition Miriam Ruiz Ponce, MSc, a predoctoral researcher at the Maimonides Biomedical Research Institute in Córdoba, Spain received one of the EULAR award for translational basic science. She developed a mouse model of fatty liver disease associated with inflammatory arthritis to evaluate the anti-inflammatory and metabolic properties of apremilast, a drug commonly used in psoriatic arthritis. 'Early results have shown that the drug has promising effects, as it partially reverses liver damage, as well as inflammation. These are the initial results, but it could be a potential treatment for inflammation and for the deleterious effects on the liver in these patients. It is an honour to receive this award, which motivates us to continue our research under the leadership of my mentor, Nuria Barbarroja Puerto, PhD, the principal investigator of the potential treatment targeting inflammation and liver damage,' she said. Chinoy disclosed financial relationships with AstraZeneca, Pfizer, PTC Therapeutics, and UCB. Furie disclosed the financial relationships with GSK and Genentech; the REGENCY study was funded by F. Hoffmann-La Roche. Sarbu and Cope disclosed having no relevant financial relationships. Turner, Cipolletta, and Ponce did not provide conflict-of-interest disclosures.

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care
Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

Yahoo

timean hour ago

  • Yahoo

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, Regeneron Pharmaceuticals announced a new and pioneering donation matching program to support Good Days, which is an independent national non-profit charitable organization. The initiative is designed to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this program, Regeneron has committed to matching donations at a one-to-one rate, up to a total of $200 million, for the remainder of the 2025 calendar year. The primary goal is to enable more patients to afford essential medicines that help protect their vision. The Retinal Vascular and Neovascular Disease Fund provides copay assistance to US patients who meet specific criteria determined by Good Days. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. The donations are not intended to incentivize the use of any particular product, and copay support is granted without regard to the specific medicine prescribed, as long as it is FDA-approved. Regeneron also facilitates access to medicines through various other initiatives, such as product support & Managed Access Programs, patient assistance programs, and collaborations with experienced stakeholders. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Protecting children online: The time to act is now
Protecting children online: The time to act is now

Yahoo

timean hour ago

  • Yahoo

Protecting children online: The time to act is now

In today's digital era, children are growing up in a world where social media are as integral to their daily lives as school or family. While technology offers tremendous opportunities for learning, creativity, and connection, it also exposes young people to significant risks that can no longer be overlooked. The consequences are deeply concerning. According to a 2023 report by the European Commission, one in three young people in the EU spends more than three hours per day on social media. This level of overexposure has been closely associated with a growing mental health issues among minors—including anxiety, depression, and low self-esteem. A 2024 study by the World Health Organisation showed that a problematic social media use among adolescents increased from 7% in 2018 to 11% in 2022. It highlights negative impacts on mental health, sleep, well-being and academic performance. Social media platforms – often built around addictive algorithms – are designed to keep young users engaged for extended periods. Constant exposure to idealised, curated content can distort self-perception, fuelling feelings of inadequacy and dissatisfaction. These are not just statistics—they reflect the genuine emotional and psychological struggles faced by an entire generation that is increasingly ill–equipped to navigate the digital world in a healthy and balanced manner. Europe has made notable progress through initiatives like the Better Internet for Kids (BIK+) strategy and the Digital Services Act (DSA). Yet, the current framework remains insufficient. The online protection of children must be elevated to a political and societal priority, underpinned by concrete and enforceable action. We must therefore move swiftly to implement a set of focused measures, starting with default privacy settings for children's accounts to reduce the risk of unsolicited contact from strangers. We also asking for ecalibrated recommender systems that prioritise explicit user feedback—such as deliberate selection of topics—to minimise the risk of children being drawn into harmful content rabbit holes. We want enhanced safety controls, including the ability for children to block or mute any user and protection from being added to group chats without their explicit consent, thereby reducing exposure to cyberbullying. Above all, mandatory age verification mechanisms must be implemented across all social networks. Such measures are essential to prevent minors from bypassing age restrictions and to substantially reduce their exposure to harmful online environments. The European Commission's recent draft guidelines on the protection of minors under the DSA mark a significant step towards a safer digital space. They offer a unique opportunity to establish age verification a a standard practice across social networks—not as an optional feature, but as a strict requirement. Enforcing age verification will equip platforms with the technical means necessary to uphold their own terms of service. It will also facilitate the enforcement of EU and national laws that set minimum age requirements for access to specific digital products or services. If we are genuinely committed to ensuring that the digital world fosters healthy development, learning, and meaningful connection—rather than becoming a breeding ground for anxiety, addiction and harm—then the decisive action must be taken now. Alexander Pröll, State Secretary for Digitalisation, Combating Antisemitism and Public Service, and the Constitution, Austria; Prof Radovan Fuchs, PhD., Minister of Science, Education and Youth, Croatia; Damir Habijan, Minister of Justice, Public Administration and Digital Transformation, Croatia; Dr Nicodemos Damianou, Deputy Minister of Research, Innovation and Digital Policy, Cyprus; Caroline Stage Olsen, Minister for Digital Affairs, Denmark; Clara Chappaz, Minister of Artificial intelligence and Digital Affairs, France; Elisabeth Borne, Minister of National Education, Higher Education and Research, France; Catherine Vautrin, Minister of Labour, Health, Solidarity, and Families, France; Karin Prien, Federal Minister of Education, Family Affairs, Senior Citizens, Women and Youth, Germany; Dimitrios Papastergiou, Minister of Digital Governance, Greece; Sofia Zacharaki, Minister of Education, Religious Affairs and Sports, Greece; Patrick O'Donovan, Minister for culture and communications, Ireland; Prof Giuseppe Valditar, Minister for Education and Merit, Italy; Alessio Butti, Undersecretary of State to the Presidency of the Council of Ministers, responsible for technological innovation and digital transition, Italy; Elisabeth Margue, Minister for Justice and Minister attached to the Prime Minister, responsible for the Media and Connectivity, Luxembourg; Claude Meisch, Minister for Education, Children and Youth Affairs, Luxembourg; Tomáš Drucker, Minister of Education, Research, Development, and Youth, Slovakia; Ksenija Klampfer, Minister of Digital Transformation, Slovenia; Vinko Logaj, Minister of Education and Care, Slovenia; Oscar López Águeda, Minister for Digital and Civil Service Transformation, Spain and María del Pilar Alegría Continente, Minister for Education and Vocational Training, Spain all coauthored this opinion article.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store